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Implication for health policy/practice/research/medical education:
The carvacrol showed promising anticandidal effects against Candida species, implying its potential in the therapy of Candida 
species infections. In addition, these results can provide insights into the mechanism of action of carvacrol against C. albicans.
Please cite this paper as: Alizadeh F, Khodavandi A, Esfandyari  S, Nouripour-Sisakht S. Analysis of ergosterol and gene 
expression profiles of sterol ∆5,6-desaturase (ERG3) and lanosterol 14α-demethylase (ERG11) in Candida albicans treated with 
carvacrol. J Herbmed Pharmacol. 2018;7(2):79-87. doi: 10.15171/jhp.2018.14
Introduction: Usually, for treatment of fungal infections, antifungals such as azoles are used, 
but one of the biggest problems faced in clinical practice is the emergence of resistance for 
most of these drugs. Antifungal drugs derived from plants may alleviate this problem. The 
aims of this study were to analyse the ergosterol and gene expression profiles of ERG genes in 
Candida albicans treated with carvacrol.
Methods: We used carvacrol and conducted a series of follow-up studies to examine the inhibitors 
of Candida species isolated from immunocompromised patients. Antifungal susceptibility test, 
time-kill study, ergosterol binding assay and ergosterol content were investigated. Eventually, 
the expression of ERG3 and ERG11genes was carried out to investigate the inhibitory properties 
of antifungal activity against Candida albicans using quantitative real time RT-PCR. 
Results: Carvacrol was able to inhibit Candida species and reduce time-kill kinetic in C. albicans. 
This phytoconstituent acted by binding to ergosterol in the fungal membrane and caused a 
reduction of 52% of the ergosterol content compared to the untreated growth control. Finally, 
carvacrol displayed significant down-regulation of ERG3 and ERG11genes in C. albicans. 
Conclusion: These results provide proof of concept for the implementation of carvacrol 
inhibitors of Candida species. In addition, ERG3 and ERG11 genes could be probable target of 
carvacrol against C. albicans.
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Introduction
Outbreaks of fungal human disease are a serious and 
costly health problem in all immunocompromised 
patients (1,2). Five Candida species including Candida 
albicans, Candida glabrata, Candida parapsilosis, Candida 
tropicalis and Candida krusei account for approx. 90% 
of identifiable invasive Candida infections. Clearly, it is 
demonstrated that albicans is the most important Candida 
species. On the other hand, several virulence factors are 
contributed to Candida pathogenicity (3-5). 
Ergosterol is neutral lipids of the fungal cellular 
membranes that regulate fluidity, function and biogenesis 
of membranes. Fungal ergosterol homeostasis is critical 
for many cellular processes including regulation of 
transcription control of ergosterol biosynthetic pathway 
genes and proteins involved in sterol processing and 
uptake. The ergosterol biosynthetic enzymes are essential 
for fungal growth and the primary target for several 
anticandidal agents. Antifungal agents in the azole class 
target the fungal cell membrane through inhibition of 
the enzyme  14α-demethylase, product of the CYP51/
ERG11, thus block the biosynthesis of ergosterol and lead 
to defects in cell membrane integrity and cellular integrity 
(6-8). 
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About 20 genes involve in the biosynthesis of ergosterol 
in fungi and there are single-copy of the C. albicans ERG 
genes in this pathway. Sterol ∆5,6-desaturase (encoded by 
ERG3) is the second last step in the ergosterol biosynthetic 
pathway that adds a double bond at the C-5 carbon of 
the B-ring structure of episterol to produce ergosta-
5,7,24(28)-trienol. The final step is the substrate of 
sterol ∆22-desaturase and sterol ∆24-reductase encoded 
by ERG5 and ERG4, respectively (7,9,10). Lanosterol 
14-demethylase (ERG11) gene is a member of cytochrome 
P450 enzyme family that is an essential enzyme for 
ergosterol synthesis. This enzyme converts lanosterol to 
ergosterol which catalyzes the oxidative removal of the 
14α-methyl group from lanosterol (11).
Plants have been a source of secondary metabolites. 
Carvacrol from the class of monoterpene phenols is 
a major component of essential oil extract from the 
Lamiaceae family with strong antimicrobial properties. It 
is demonstrated that carvacrol has been inhibitory activity 
against C. albicans. The antifungal mechanism action of 
carvacrol is cell membrane disruption by targeting and 
binding to membrane ergosterol (12-15). 
During recent years, insight into the antifungal 
mechanism of natural products has markedly increased. 
In the current study, we conducted a series of follow-up 
studies to investigate the antifungal inhibitory effects 
of carvacrol against Candida species isolated from 
immunocompromised patients. In addition, ergosterol 
binding assay, ergosterol quantification and expression 
profiles of selected genes involved in the ergosterol 
biosynthetic pathway of C. albicans treated with carvacrol 
were analyzed.
Materials and Methods
 Clinical isolates of C. albicans (Ca2, Ca3, Ca5, Ca10), C. 
krusei (Ck1, Ck24, Ck25, Ck26) and C. tropicalis (Ct7, Ct9, 
Ct11, Ct17) were obtained from immunocompromised 
patients who admitted in Shahid Beheshti affiliated 
to Yasooj University of Medical Sciences. Written 
informed consent was obtained from patients for the 
use of the samples in research. Isolates were cultured in 
Sabouraud dextrose broth (SDB, Difco Laboratories, 
Detroit, Michigan). The identities of the clinical isolates 
of Candida were confirmed by phenotypic (16) and 
molecular techniques (17). Briefly, clinical isolates were 
plated on CHROMagar Candida medium (CHROMagar 
Company, France) to check for purity and the reliability 
of Candida species were confirmed by DNA sequencing. 
C. albicans ATCC 14053, C. krusei ATCC 6258 and C. 
tropicalis ATCC 750 were employed as the strain-controls. 
Phenotypic methods for clinical isolates identification
Phenotypic methods including microscopic and 
macroscopic morphology, germ tube formation, 
carbohydrate and nitrate assimilations, carbohydrate 
fermentation and urease test were carried out to identities 
of the clinical isolates (16).
DNA-sequencing techniques for clinical isolates 
identif ication
The universal fungal primers ITS1 (5’- TCC GTA GGT 
GAA CCT GCG G-3’) and ITS4 (5’- TCC TCC GCT TAT 
TGA TAT GC-3’) were used for DNA amplification (17). 
The amplified PCR products were confirmed by DNA 
sequencing. The sequence homology was detected using 
the nucleotide BLAST program.
Antifungal agents and susceptibility testing
Carvacrol and fluconazole were obtained from Sigma 
Chemicals Co. (St. Louis, MO). Antifungal disk diffusion 
susceptibility test and broth microdilution antifungal 
susceptibility test were performed as described in the CLSI 
guideline (M44-A2 and M27-A3, method for antifungal 
disk diffusion susceptibility testing of yeasts and reference 
method for broth dilution susceptibility testing of yeasts, 
respectively) (18,19).
Time-kill study
The time-kill study of carvacrol was performed with the 
methodology described by Khodavandi et al (20). The 
C. albicans ATCC 14053 was chosen from the results of 
susceptibility testing. To determine the kinetics of fungal 
death, 4 mL of 1 × 106 C. albicans ATCC dissolved in RPMI 
1640 and mixed with the different concentrations based 
on MIC (MIC and ½× MIC) of carvacrol. After 0, 2, 4, 6, 8, 
10, 12, 24 and 48 hours incubation at 35°C, 100 µL of each 
mixture was collected and 10-fold serial dilutions were 
made and plated on Sabouraud dextrose agar (SDA, Difco 
Laboratories). Eventually, colonies were counted after 24 
hours incubation at 37°C and the CFU were calculated. 
Furthermore, fluconazole was used as a control drug. 
Ergosterol binding assay
Ergosterol binding properties of antifungal agents were 
performed using the following method by Escalante et 
al (21). The C. albicans ATCC 14053 was chosen from 
the results of susceptibility testing. The MIC of carvacrol 
against C. albicans ATCC was determined in accordance 
with the guidelines of CLSI M27-A3, at different 
concentrations (50-250 µg/mL) of ergosterol (Sigma). 
Fluconazole was used as a control drug. 
Ergosterol quantification
The ergosterol quantification in the cell membrane of C. 
albicans was performed by method as described by Santos 
et al (22). At first, 25 mg of the C. albicans cell mass was 
added to carvacrol with different MIC concentrations 
(MIC and ½× MIC) in polypropylene tubes and incubated 
at 35°C for 24 hours. The C. albicans cells were harvested 
by centrifugation at 1643 g for 5 minutes at 4°C, and 
washed once in a sterile distilled water. The net wet weight 
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of the cell pellet was determined. Lipids were extracted 
with 3 mL of ethanolic solution of potassium hydroxide 
25% in C. albicans cell mass and incubated in an 85°C 
water bath for 1 hours. After incubation, the tubes were 
incubated at room temperature. Finally, 1 mL of sterile 
water and 3 mL of n-heptane (Sigma) were added and 
vortexed for 3 minutes. The aqueous fraction was removed 
with a pipette, and the spectrophotometric measurements 
were performed at 282 and 230 nm. The calibration 
curve of standard ergosterol was constructed and used 
to determine the amount of ergosterol. The results of the 
quantitative determination of ergosterol were expressed as 
the percentage of ergosterol in treated cells compared to 
untreated control ones.
Quantitation of gene expression levels
Gene expression levels of ERG3 (GenBank accession 
number AF069752) and ERG11 (GenBank accession 
number X13296) were measured using quantitative 
real-time RT-PCR, as described previously (23,24) in 
C. albicans ATCC 14053 cells treated with carvacrol at 
different concentrations based on MIC (MIC and ½× 
MIC). Briefly, single-stranded cDNA was synthesized 
from 0.5 µg extracted RNA using M-MuLV reverse 
transcriptase and random hexamer oligonucleotides 
(Fermentas, USA). Oligonucleotide primers were listed in 
Table 1. The primers for ERG3, ERG11 and β actin were 
amplified by PCR using ™SYBR Green qPCR Master Mix 
(Fermentas, EU) in a Bio-Rad MiniOpticonTM system 
(USA), according to the manufacturer’s protocol. Relative 
gene expression data were analyzed by the Pfaffl method. 
Fluconazole was also used as a control drug.
Statistical analysis
Data were analyzed using the statistical software SPSS 
20.0 for Windows (SPSS Inc., Chicago, IL, USA). Data 
were expressed as mean values ± standard deviations (SD) 
or standard error (SE) from three independent replicate 
experiments. Results were statistically analyzed using one-
way analysis of variance (ANOVA) and Tukey’s honestly 
significant difference (HSD) test. P values of ≤0.05 were 
considered statistically significant.
Results
Studies of phenotypic and genotypic characteristics
Clinical yeast isolates selected from SDA, were 
phenotypically identified to species level. Macroscopically, 
colonies of Candida (on the surface of SDA) are cream 
to yellow in color. Phenotypic characteristics of three 
identified Candida species is shown in Table 2. The 
reliability of C. albicans, C. krusei and C. tropicalis was 
confirmed by DNA sequencing via the non-redundant 
nucleotide sequences from Gen Bank. The sequences 
displayed high homology and confirmed to have 100% 
identify with the respective gene sequence.
Antifungal susceptibility
The antimicrobial activity of carvacrol compared with 
standard drug (fluconazole), was assessed by the disk 
diffusion susceptibility test against clinical isolates of 
Candida species. The results of sensitivity to antifungal 
drugs (diameter of inhibition zone in mm) are summarized 
in Table 3. The results revealed that carvacrol could able 
to show antimicrobial properties against clinical isolates 
of Candida species compared to the standard antifungal 
agent (fluconazole) at 30 µg/mL concentration. However, 
the antifungal activity of the carvacrol was found to 
be potent at 20 µg/mL concentration for isolates of C. 
albicans. 
Table 4 summarizes the MICs of the antifungal drugs 
tested against clinical isolates of Candida species. The 
MIC of the carvacrol was 25 µg/mL for 100% of the 
clinical isolates of C. albicans evaluated. However, the 
MIC of the carvacrol for clinical isolates of C. krusei and 
C. tropicalis were ranged from 25-50 µg/mL and 50-100 
µg/mL, respectively. From Table 4, it can be seen that 2 of 
5 clinical isolates of C. krusei and 2 of 5 clinical isolates of 
C. tropicalis were resistant to fluconazole.
Time kill study
The dynamic antifungal effect of carvacrol against Candida 
species was confirmed by time kill studies. The antifungal 
effect of carvacrol was depicted by time kill curves with 
log10 CFU of cells/mL as Y-axis and time as X-axis (Figure 
1). The results show the potency of carvacrol in decreasing 
the cell number of Candida species after 0, 2, 4, 6, 8, 10, 12, 
24 and 48 hours compared to untreated control (P ≤ 0.05). 
At 48th, the log10 CFU value was reduced more than 25- 
and 20-fold in the C. albicans ATCC treated with MIC and 
½× MIC of carvacrol, respectively. The log10 CFU values 
were no significant difference among these three species. 
Effect of carvacrol on ergosterol binding properties
The results of the ergosterol binding assay showed 
Table 1. Oligonucleotide primers used for PCR
Primer Orientation Sequence Reference
ERG3 Forward 5' TCC AGT TGA TGG GTT CTT CC 3' (24)
Reverse 5' GGA CAG TGT GAC AAG CGG TA 3' 
ERG11 Forward 5' TGG AGA CGT GAT GCT G 3′ (23)
Reverse 5′ AGT ATG TTG ACC ACC CAT AA3′ 
ACT Forward 5' GAG TTG CTC CAG AAG AAC ATC CAG 3' (24)
Reverse 5' TGA GTA ACA CCA TCA CCA GAA TCC 3' 
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Table 2. Phenotypic characteristics of Candida albicans, Candida krusei and Candida tropicalis
Isolates
Germ tube 
production
Carbohydrate and nitrate assimilations Carbohydrate fermentation
Urease CHROM-agar 
colony colorGLU MAL SUC LAC TER XYL STA KNO3 GLU MAL SUC LAC TER 
C. albicans ATCC + + + + - + + + - + + - - + - Blue-green
Ca2 + + + + - + + + - + + - - + - Blue-green
Ca3 + + + + - + + + - + + - - + - Blue-green
Ca5 + + + + - + + + - + + - - + - Blue-green
Ca10 + + + + - + + + - + + - - + - Blue-green
C. krusei ATCC - + - - - - - - - + - - - - - Pink-purple
Ck1 - + - - - - - - - + - - - - - Pink-purple
Ck24 - + - - - - - - - + - - - - - Pink-purple
Ck25 - + - - - - - - - + - - - - - Pink-purple
Ck26 - + - - - - - - - + - - - - - Pink-purple
C. tropicalis ATCC - + + + - + + + - + + + - + - Dark blue
Ct7 - + + + - + + + - + + + - + - Dark blue
Ct9 - + + + - + + + - + + + - + - Dark blue
Ct11 - + + + - + + + - + + + - + - Dark blue
Ct17 - + + + - + + + - + + + - + - Dark blue
GLU: Glucose; MAL: Maltose; SUC: Sucrose; LAC: Lactose; TRE: Trehalose; XYL: Xylose; STA:  starch. Ca: Clinical isolates of C. albicans; Ck: Clinical isolates of C. krusei; Ct: Clinical isolates of C. tropicalis.
Analysis of ergosterol and gene expression profiles of ERG genes in Candida albicans treated with carvacrol
Journal of Herbmed Pharmacology, Volume 7, Number 2, April 2018http://www.herbmedpharmacol.com 83
Table 3. Antimicrobial activities of carvacrol against isolates of Candida albicans, Candida krusei and Candida tropicalis at different concentration
Isolates C. albicans ATCC Ca2 Ca3 Ca5 Ca10 C. krusei ATCC Ck1 Ck24 Ck25 Ck26 C. tropicalis ATCC Ct7 Ct9 Ct11 Ct17
Inhibition 
zone (mm)
Carvacorol
10 μg/mL
6.00 ± 0.00 6.00 ± 0.00
6.00 ± 
0.00
6.00 ± 
0.00
6.00 ± 
0.00 6.00 ± 0.00
6.00 ± 
0.00
6.00 ± 
0.00
6.00 ± 
0.00
6.00 ± 
0.00 6.00 ± 0.00
6.00 ± 
0.00
6.00 ± 
0.00
6.00 ± 
0.00
6.00 ± 
0.00
20 μg/mL
11.00 ± 0.20 8.00 ± 0.20
8.00 ± 
0.10
7 .00 ± 
0.20
10.00 ± 
0.20 6.00 ± 0.00
6.00 ± 
0.00
6.00 ± 
0.00
6.00 ± 
0.00
6.00 ± 
0.00 6.00 ± 0.00
6.00 ± 
0.00
6.00 ± 
0.00
6.00 ± 
0.00
6.00 ± 
0.00
30 μg/mL
16 ± 0.10 14.50 ± 0.11
14.00 ± 
0.20
13.80 ± 
0.22
15 ± 
0.10 14.10 ± 0.11
10.10 ± 
0.10
11.50 ± 
0.24
13.40 ± 
0.20
11.80 ± 
0.10 14.70 ± 0.12
12.30 ± 
0.21
13.50 ± 
0.00
12.80 ± 
0.11
11.50 ± 
0.00
Fluconazole
25 μg/mL
15.70 ± 0.10 13.90 ± 0.20
14.70 ± 
0.11
13.00 ± 
0.20
13.00 ± 
0.20 13.10 ± 0.23
9.00 ± 
0.00
10.20 ± 
0.10
1250 ± 
0.11
10.70 ± 
0.00 14.70 ± 0.13
12.50 ± 
0.10
13.70 ± 
0.11
13.40 ± 
0.00
12.00 ± 
0.11
Ca: Clinical isolates of C. albicans; Ck: Clinical isolates of C. krusei; Ct: Clinical isolates of C. tropicalis.
Data are means ± standard deviation of three independent experiments.
Table 4. Relative MIC (μg/mL) values of carvacrol against isolates of Candida albicans, Candida krusei and Candida tropicalis
Antifungals/ Isolates C. albicans ATCC Ca2 Ca3 Ca5 Ca10 C. krusei ATCC Ck1 Ck24 Ck25 Ck26 C. tropicalis ATCC Ct7 Ct9 Ct11 Ct17
Carvacorol MIC50 6.25 12.5 6.25 12.5 6.25 12.5 12.5 12.5 12.5 12.5 25 25 25 25 50
MIC90 25 25 25 25 25 25 50 50 25 25 50 50 50 50 100
Fluconazole MIC50 0.125 0.125 0.25 0.25 0.25 0.25 2 1 0.25 0.25 0.5 1 2 1 2
MIC90 4 8 8 16 8 16 64 64 32 32 8 16 64 16 64
Ca: Clinical isolates of C. albicans; Ck: Clinical isolates of C. krusei; Ct: Clinical isolates of C. tropicalis.
Data are means ± standard deviation of three independent experiments.
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(Figure 2) that the MIC values of carvacrol for C. albicans 
ATCC cells a 4-fold increase of MIC was observed in the 
presence of 250 and 300 µg/mL of exogenous ergosterol. 
In addition, a 5-fold increase of MIC was observed for the 
control drug (fluconazole) in the presence of 250 and 300 
µg/mL of exogenous ergosterol.
Quantitation of Candida albicans ergosterol content
To further investigation of the action of the carvacrol 
on the C. albicans cell membrane, the ergosterol content 
24 
 
 
 
 Figure 2. Effect of different concentrations of exogenous ergosterol (50-300 µg/mL) on the 
MIC of carvacrol and fluconazole against Candida albicans ATCC 14053. 
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igure 1. Time kill curves of carvacrol and fluconazole in different 
concentration based on MIC (MIC and ½× MIC) against (A) Candida 
albicans ATCC 14053, (B) Candida krusei ATCC 6258 and (C) Candida 
tropicalis ATCC 750. Data are means with standard error from three 
independent experiments in triplicate assays. Statistically significant 
differences between the treatments and the control are indicated with 
an asterisk (P ≤ 0.05).
Figure 3. Percent ergosterol levels of Candida albicans ATCC 14053 
after 24 hours of treatment with different concentrations of antifungal 
agents. Data are means with standard error from three independent 
experiments in triplicate assays. Statistically significant differences 
between the treatments and the control are indicated with an asterisk 
(P ≤ 0.05). 
Figure 2. Effect of different concentrations of exogenous ergosterol 
(50-300 µg/mL) on the MIC of carvacrol and fluconazole against 
Candida albicans ATCC 14053.
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was evaluated in C. albicans ATCC 14053 cells treated 
with the different MIC-concentrations of carvacrol (MIC 
and ½× MIC). Figure 3 demonstrates treatment with 
carvacrol caused a reduction of 52% of the ergosterol 
content compared to the untreated growth control. The 
ergosterol content increased with the decrease of carvacrol 
concentration (P ≤ 0.05). The C. albicans cells treated with 
fluconazole reduced the ergosterol contents in 58%. When 
the fluconazole concentration equal to ½ MIC was used, 
leads to lower ergosterol levels.
Gene expression analysis
In the present study, C. albicans ATCC was treated with 
different concentrations of carvacrol and fluconazole (MIC 
and ½× MIC). We monitored the expression levels of ERG3 
in C. albicans cells by quantitative real-time RT-PCR. The 
expression levels of ERG3, a sterol ∆5,6-desaturase gene, 
down regulate (P ≤ 0.05) in the C. albicans cells treated 
with different concentrations of carvacrol and fluconazole 
(Figure 4). C. albicans gene expression patterns were 
similar in response to the antifungal activity of carvacrol 
and fluconazole. The expression levels of ERG3 were 
demonstrated the lowest fold change expression in C. 
albicans treated with carvacrol compared to fluconazole 
at concentrations equal to MIC. While the fold changes 
in terms of ERG3 expression to untreated control for ½× 
MIC of carvacrol was higher compared to fluconazole. 
The authenticity of the PCR products was verified by DNA 
sequencing. The sequences confirmed high homology to 
the related genes in Gene Bank.
Discussion
According to the literature previously demonstrated that 
carvacrol has been found to be active against C. albicans 
(12-15). Fluconazole was used as a positive control because 
it is one of the most commonly used antifungal agents for 
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the treatment of Candida species infections (25). Our 
findings consistent with previous studies of antifungal 
activity of carvacrol could inhibit Candida species growth 
(12-15,26). The authors studied two clinical isolates of 
C. krusei and two clinical isolates of C. tropicalis which 
presented MIC= 64 µg/mL for fluconazole. However, the 
antimicrobial activity of the carvacrol was found to be 
potent against fluconazole-resistant Candida species. Our 
favorable results are, at least in partial, in agreement with 
Gallucci et al. ones (26), who demonstrated that carvacrol 
had the highest anti-Candida activity against fluconazole-
resistant Candida species. These results parallel the work 
of Rao et al (27), showing that carvacrol was the most 
effective in killing C. albicans. In addition, the tested 
antifungals on the C. krusei and C. tropicalis completely 
reduced the number of yeast form in time kill study. In the 
literature, carvacrol has been found to be active against C. 
krusei and C. tropicalis (26).
The effect of ergosterol on carvacrol was investigated 
using the broth microdilution technique. Findings from 
the MIC values of carvacrol for C. albicans ATCC cells 
exhibited a 4-fold increase of MIC. This effect of ergosterol 
is in good agreement with the Lima et al (14) report. 
The ergosterol quantification assay revealed that reduction 
of the ergosterol  contents caused by carvacrol and 
fluconazole at different concentration of MIC. This effect 
helps explain the demonstrated concentration dependent 
on antifungals, since higher concentrations of carvacrol 
and fluconazole lead to lower ergosterol contents. The 
mechanism proposed for mode of actions of carvacrol and 
fluconazole are inhibition of fungal sterol biosynthesis. 
Considering ergosterol as an important sterol found in cell 
membranes of fungi, changes in its biosynthetic pathway 
may also prove lethal to the fungal cell (14,28,29). 
Down-regulated expression of ERG3 and ERG11 genes 
were found in C. albicans ATCC treated with carvacrol 
Figure 4. Relative quantitation of ERG3 and ERG11 genes normalized 
to house-keeping gene, actin in Candida albicans ATCC 14053 after 
24 h of treatment with different concentrations of antifungal agents 
by real time RT-PCR. Data are means of fold changes with standard 
error from three independent experiments amplified in triplicates. 
Statistically significant differences between the treatments and the 
control are indicated with an asterisk (P ≤ 0.05). 
and fluconazole at different MIC concentrations. The 
down-regulated sterol ∆5,6-desaturase and lanosterol 
14α-demethylase genes were consistent with the ergosterol 
binding properties and ergosterol content. Importantly, 
carvacrol and fluconazole significantly reduced C. 
albicans ATCC ergosterol related properties compared 
with untreated control. Few studies have investigated 
the expression of ERG3 and ERG11 genes in C. albicans 
treated with antifungals. Our results are, in partial, 
in agreement with Khodavandi et al ones (20), who 
showed that fluconazole in combination with terbinafine 
significantly reduced the expression of ERG1, 3, and 11 in 
C. albicans. The effect of combination of tunicamycin and 
amphotericin B has significantly decreased the expression 
level of MP65 and ERG3 in C. albicans and C. dubliniensis 
(30). Yang et al (31) investigated the effect of citral on five 
ergosterol biosynthetic pathway genes (ERG7, ERG11, 
ERG6, ERG3 and ERG5) in Penicillium digitatum. P. 
digitatum treated with citral greatly affected the expression 
levels of ergosterol biosynthetic pathway genes consistent 
with a decrease in ergosterol content and accumulation of 
massive lanosterol. Furthermore, ERG3, ERG4 and ERG5 
were downregulated in Saccharomyces cerevisiae treated 
with fluconazole (32). A previous study showed that 
the five major genes: ABC transporter genes CDR1 and 
CDR2, major facilitator efflux gene MDR1 and ergosterol 
biosynthesis genes ERG3 and ERG11 are responsible for 
antifungal resistance in C. albicans (33).
This study supports the view that carvacrol exerts its 
antifungal activity on the cell membrane of C. albicans 
by inhibition of ergosterol biosynthesis. Whether these 
events reflect the potential of carvacrol for inhibition of 
ergosterol biosynthesis in C. albicans which differentially 
expresses a specific gene, requires further dissection. In 
addition, ERG3 and ERG11 genes could be probable 
molecular targets for carvacrol in C. albicans. Greater 
knowledge of molecular mechanisms of antifungal effects 
may serve as a guide for future in the development of new 
therapeutic strategies. 
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